The shares of Genworth Financial, Inc. (NYSE:GNW) has been pegged with a rating of Market Perform by Wells Fargo in its latest research note that was published on September 23rd, 2016. Wells Fargo wasn’t the only research firm that published a report of Genworth Financial, Inc., with other equities research analysts also giving their opinion on the stock. Compass Point advised investors in its research note published on May 5th, 2016, to Buy the GNW stock while also putting a $5.25 price target. The stock had earned Buy rating from Compass Point when it published its report on February 8th, 2016. That day the Compass Point set price target on the stock to $5.50. The stock was given Neutral rating by Goldman in its report released on November 17th, 2015, the day when the price target on the stock was placed at $5. UBS was of a view that GNW is Sell in its latest report on November 4th, 2015 while giving it a price target of $4.25. UBS thinks that GNW is worth Neutral rating. This was contained in the firm’s report on September 8th, 2015 in which the stock’s price target was also moved to $5.25.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $4.00. The price of the stock the last time has raised by 35.29% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 55.17.
The shares of the company dipped by -2.01% during the trading session on Thursday, reaching a low of $3.83 while ending the day at $3.91. During the trading session, a total of 3.14 million shares were traded which represents a 6.88% incline from the average session volume which is 3.37M shares. GNW had ended its last session trading at 3.99. Genworth Financial, Inc. currently has a market cap of $1.96B, while its P/E ratio stands at 11.74, while its P/E earnings growth sits at 0.23, with a beta of 1.73. Genworth Financial, Inc. debt-to-equity ratio currently stands at 0.33, while its quick ratio hovers at . GNW 52-week low price stands at $2.89 while its 52-week high price is $5.02.
The company in its last quarterly report recorded $0.24 earnings per share which is below the $0.30 predicted by most analysts. The Genworth Financial, Inc. generated $2,204.00 million in revenue during the last quarter, which is slightly higher than the $2,114.50 million predicted by analysts. In the second quarter last year, the firm recorded -$0.58 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 341.67%. Genworth Financial, Inc. has the potential to record 0.33 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Evercore ISI published a research note on July 16th, 2019 where it informed investors and clients that MetLife, Inc. (NYSE:MET) is now rated as In-line. Compass Point also rated MET as Reiterated on May 5th, 2016, with its price target of $5.25 suggesting that MET could surge by 8.71% from its current share price. Even though the stock has been trading at $49.42/share, analysts expect it to surge higher by -2.21% to reach $52.94/share. It started the day trading at $51.16 and traded between $47.91 and $48.33 throughout the trading session.
A look at its technical shows that MET’s 50-day SMA is 49.15 while its 200-day SMA stands at 45.26. The stock has a high of $50.94 for the year while the low is $37.76. The company’s P/E ratio currently sits at 9.40, while the P/B ratio is 0.79. At the moment, only of MetLife, Inc. shares were sold short. The company’s average trading volume currently stands at 4.43M shares, which means that the short-interest ratio is just 2.27 days. Over the past seven days, the company moved, with its shift of -3.61%. Looking further, the stock has raised 1.94% over the past 90 days while it gained 5.82% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc sold more MET shares, decreasing its portfolio by -1.20% during the last quarter. This move now sees The Vanguard Group Inc selling -793,672 shares in the last quarter, thus it now holds 65,402,921 shares of MET, with a total valuation of $3,248,563,086. Dodge Cox meanwhile bought more MET shares in the recently filed quarter, changing its stake to $2,306,137,520 worth of shares. SSgA Funds Management Inc followed the path by decreasing its MET portfolio by -0.58% in the quarter. This means that SSgA Funds Management Inc sold -267,064 shares in the last quarter and now controls 45,706,359 shares of the MET stock, with the valuation hitting $2,270,234,852.
Similarly, BlackRock Fund Advisors decreased its MetLife, Inc. shares by -4.29% during the recently filed quarter. After selling -1,783,653 shares in the last quarter, the firm now controls 39,801,907 shares of MetLife, Inc. which are valued at $1,976,960,721. In the same vein, Wellington Management Co LLP decreased its MetLife, Inc. shares by during the most recent reported quarter. The firm sold -10,091,912 shares during the quarter which decreased its stakes to 30,066,809 shares and is now valued at $1,493,418,403. Following these latest developments, around 0.10% of MetLife, Inc. stocks are owned by institutional investors and hedge funds.